Quarterly Dividends, Collaborations, and New Distribution Agreements Highlight Potential Growth - Research Report on Life

Quarterly Dividends, Collaborations, and New Distribution Agreements Highlight
    Potential Growth - Research Report on Life Technologies, Thermo Fisher
              Scientific, Agilent, Quest Diagnostics, and Zimmer

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 17, 2013

NEW YORK, July 17, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Life
Technologies Corporation (NASDAQ: LIFE), Thermo Fisher Scientific, Inc. (NYSE:
TMO), Agilent Technologies Inc. (NYSE: A), Quest Diagnostics Inc. (NYSE: DGX),
and Zimmer Holdings, Inc. (NYSE: ZMH). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Life Technologies Corporation Research Report

On July 2, 2013, Life Technologies Corporation (Life Technologies) announced
that its new Ion AmpliSeq Exome Kit delivers the best exome sequencing
performance in the industry, with up to 98% of bases covered at 10x, and up to
96% of bases covered at 20x, for a single exome. Gregg Fergus, Ion Torrent
President and COO, stated, "The Ion AmpliSeq Exome Kit with the Ion Proton
System and the upcoming Ion Chef System for automated template and chip
loading, provide an exome solution that is superior on nearly every metric for
lab scientists, core lab directors and large genome centers." Fergus
continued, "More importantly, we are still scaling and improving at an
incredible pace each and every quarter." The Full Research Report on Life
Technologies Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/d9de_LIFE]

--

Thermo Fisher Scientific, Inc. Research Report

On July 12, 2013, Thermo Fisher Scientific, Inc. (Thermo Fisher) announced
that its Board of Directors has declared a quarterly cash dividend of $0.15
per share. Thermo Fisher reported that the dividends will be payable on
October 15, 2013 to shareholders on record as of September 16, 2013. The Full
Research Report on Thermo Fisher Scientific, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/45ea_TMO]

--

Agilent Technologies Inc. Research Report

On July 9, 2013, Agilent Technologies Inc. (Agilent) announced that the
Shanghai Integrated Circuit Research and Development Center (ICRD) is
utilizing the Company's Model Builder Program and Model Quality Assurance
software for model extraction and verification at 45-nm process nodes.
Shoumian Chen, Vice President of Shanghai ICRD, commented, "As a loyal Agilent
customer, we are proud to be using MBP and MQA software." Chen added, "The
major enhancements in MBP/MQA 2013.01 enable us to complete the tedious
aspects of our modeling work much more efficiently. Model Reviewer, for
example, allows us to standardize various aspects of device modeling in a team
environment. Because it is based on Agilent's unified end-to-end device
modeling platform, it ensures seamless data transfers during the modeling
process." The Full Research Report on Agilent Technologies Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.WSReports.com/r/full_research_report/075f_A]

--

Quest Diagnostics Inc. Research Report

On July 10, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced its
collaboration with the US Centers for Disease Control and Prevention (CDC) to
improve public health analysis of hepatitis C screening, diagnosis, and
treatment, based on analysis of the company's national hepatitis C virus
diagnostic information. Jay Wohlgemuth, M.D., Senior Vice President of Science
and Innovation at Quest Diagnostics, said, "Our collaboration with the CDC
underscores the importance of using diagnostic information to derive useful
insights enabling effective prevention, detection and management programs for
diseases with a significant impact on public health." John W. Ward, M.D.,
Director of CDC's Division of Viral Hepatitis, stated, "With 3 million
Americans living with hepatitis C and up to 3 out of 4 who don't know they are
infected, increased testing is critical to ensure that those who are infected
receive life-saving care and treatment." The Full Research Report on Quest
Diagnostics Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/0cb6_DGX]

--

Zimmer Holdings, Inc. Research Report

On July 10, 2013, Zimmer Holdings, Inc. (Zimmer) announced that it has started
the distribution of the APEX Spine System, a comprehensive set of implants and
instruments designed to safely and effectively correct a broad range of spinal
deformities, as well as complex and degenerative spinal diseases.
As per the terms of the long-term agreement with SpineCraft, Zimmer will
exclusively market the APEX Spine System to healthcare organizations across
the United States, Canada, Australia and New Zealand. Steve Healy, President
of Zimmer Spin, commented, "The APEX Spine System represents a true union of
intuitive design and engineering excellence." Healy continued, "These
innovative implants and instrumentation offer powerful correction capabilities
with excellent intraoperative flexibility. This state-of-the-art pedicle
fixation system represents a natural fit for Zimmer Spine's expanding
portfolio, enabling surgeons to meet the unique needs of their complex spine
and deformity patients, as well as patients with degenerative pathologies."
The Full Research Report on Zimmer Holdings, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/9cbd_ZMH]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.